For example [28], following BRAF inhibitor therapy in BRAF V600 mutant melanoma, individual tumors were found to develop multiple resistance events, including NRAS and MEK1 mutations in one patient and two distinct NRAS mutations in another. The gene discussed is MAP2K1; the disease is melanoma.